Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2025-12-03 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Zai Lab Limited regarding the grant of share options and restricted share units to employees under their 2024 Equity Incentive Plan. It details the number of grants, exercise prices, vesting periods, and compliance with the Hong Kong Stock Exchange Listing Rules (specifically Rules 17.06A, 17.06B, and 17.06C). While it involves equity, it is not a director's dealing (as the grantees are not directors or senior managers) nor a share issue/capital change (as it is a grant of options/RSUs). It fits best under 'Regulatory Filings' as a standard corporate announcement required by listing rules for equity incentive grants.
2025-12-03 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 100% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It details a change in the company's issued shares due to the issuance of new shares under equity incentive plans. This type of filing is specifically used to report changes in share capital and issued shares, which falls under the 'Share Issue/Capital Change' category.
2025-11-19 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zai Lab Limited regarding the grant of share options and restricted share units (RSUs) to employees under their 2024 Equity Incentive Plan. It details the number of options/units granted, the grantees, vesting periods, and listing rule implications. While this involves equity, it is a standard regulatory disclosure required by the Hong Kong Stock Exchange for share-based incentive grants. Since it does not fit into specific categories like 'Director's Dealing' (as these are employees, not directors) or 'Share Issue/Capital Change' (as it is a grant of options/units rather than a new issuance of shares), it falls under the general regulatory announcement category.
2025-11-11 English
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q, which is the standard U.S. SEC filing for quarterly financial reports. Although it is presented as an 'Overseas Regulatory Announcement' in the context of the Hong Kong Stock Exchange, the content itself is the full Form 10-Q, including financial statements, management's discussion and analysis (MD&A), and other required disclosures for the quarter ended September 30, 2025. Per the filing definitions, this qualifies as an Interim / Quarterly Report (IR). Q3 2025
2025-11-06 English
UNAUDITED RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND CORPORATE UPDATES
Earnings Release Classification · 100% confidence The document is a comprehensive announcement of financial results for the third quarter of 2025, including detailed revenue breakdowns, operating expenses, net loss, and forward-looking corporate updates. It is titled 'UNAUDITED RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND CORPORATE UPDATES' and contains detailed financial tables and management commentary. While it is an announcement, it contains the full set of quarterly financial results rather than just a notice of publication, fitting the definition of an Earnings Release (ER). Q3 2025
2025-11-06 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 'Annual Report' or 'Earnings Release' but is a recurring regulatory disclosure mandated by the Exchange Listing Rules. Therefore, it is classified as a Regulatory Filing (RNS).
2025-11-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.